jili slot demo
Trump 2.0 has Cabinet and executive branch of different ideas and eclectic personalitiesIn this article KSS Follow your favorite stocks CREATE FREE ACCOUNT Incoming Kohl's CEO Ashley Buchanan and current CEO Tom Kingsbury. Courtesy: Michael's | Kohl's Kohl's is getting a new CEO, its third since 2018. The off-mall department store's current CEO Tom Kingsbury is stepping down effective Jan. 15. He will leave the position he held first on an interim basis starting in late 2022, and then permanently since early 2023. Michaels CEO Ashley Buchanan will take over the top job at Kohl's as Kingsbury departs, after leading the crafting retailer since 2020. Prior to his time at Michaels, Buchanan was at Walmart and its Sam's Club division for 13 years. Kohl's shares fell about 3% in extended trading following the announcement. At the world's largest retailer, he held the roles of chief merchandising and chief operating officer for Walmart U.S. e-commerce and chief merchant at Sam's Club before that. Buchanan is currently on the board of Macy's, but will be stepping down from that role. Kingsbury will remain with Kohl's in an advisory role to Buchanan and stay on the board until he retires in May. Kohl's doesn't intend to replace Kingsbury and will reduce the board size by one seat. Buchanan will step in just after the critical holidays end and as the retailer closes its fiscal year. There's a lot of work to be done at a time when department stores are struggling to resonate with shoppers who have more options than ever before. While Kohl's off-mall physical format has insulated it a bit more than other department stores, it has had a difficult several years. Kohl's shares fell 17% during Kingsbury's interim period from Dec. 2, 2022 to Feb. 2, 2023 and then dropped a further 45% since. Kingsbury hasn't been able to return sales to growth at Kohl's. Its comparable store sales, a key metric for retailers, have fallen for the past 10 quarters. Kingsbury took over as CEO after Michelle Gass left Kohl's to become president and then eventual CEO of Levi Strauss. Kingsbury had been a member of the Kohl's board since 2021. He previously served as CEO of Burlington Stores from 2008 to 2019.Restaurant Brands International's executive chairman sells $2.9m in stock
Beirut: Hezbollah fired at least 185 rockets and other projectiles into Israel on Sunday, wounding seven people in the militant group's heaviest barrage in several days, in response to deadly Israeli strikes in Beirut while negotiators pressed on with cease-fire efforts to halt the all-out war. Meanwhile, an Israeli strike on a Lebanese army centre killed one soldier and wounded 18 others on the southwestern coastal road between Tyre and Naqoura, Lebanon's military said. Israel's military expressed regret and said the strike occurred in an area of combat against Hezbollah, adding that its operations are directed solely against the militants. The strike was under review. Israeli strikes have killed over 40 Lebanese troops since the start of the war between Israel and Hezbollah, even as Lebanon's military has largely kept to the sidelines. Lebanon's caretaker prime minister, Najib Mikati, condemned the latest strike as an assault on US-led cease-fire efforts, calling it a "direct, bloody message rejecting all efforts and ongoing contacts" to end the war. Hezbollah fires rockets after strikes on Beirut Hezbollah began firing rockets, missiles and drones into Israel after Hamas' October 7, 2023, attack out of the Gaza Strip ignited the war there. Hezbollah has portrayed the attacks as an act of solidarity with the Palestinians and Hamas. Iran supports both armed groups. Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Marketing Digital Marketing Masterclass by Neil Patel By - Neil Patel, Co-Founder and Author at Neil Patel Digital Digital Marketing Guru View Program Web Development Advanced C++ Mastery: OOPs and Template Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Advanced Excel Course - Financial Calculations & Excel Made Easy By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Future of Marketing & Branding Masterclass By - Dr. David Aaker, Professor Emeritus at the Haas School of Business, UC Berkeley, Author | Speaker | Thought Leader | Branding Consultant View Program Data Science MySQL for Beginners: Learn Data Science and Analytics Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Intermediate C++ Skills: Master Pointers, Structures and File Stream By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Finance AI and Generative AI for Finance By - Hariom Tatsat, Vice President- Quantitative Analytics at Barclays View Program Leadership From Idea to Product: A Startup Development Guide By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy for Non-Finance Executives By - CA Raja, Chartered Accountant | Financial Management Educator | Former AVP - Credit, SBI View Program Finance Startup Fundraising: Essential Tactics for Securing Capital By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Leadership Boosting Startup Revenue with 6 AI-Powered Sales Automation Techniques By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Tally Prime & GST Accounting: Complete Guide By - CA Raj K Agrawal, Chartered Accountant View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) ChatGPT Mastery from Zero to Hero: The Complete AI Course By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Israel has launched retaliatory airstrikes at Hezbollah, and in September the low-level conflict erupted into all-out war as Israel launched waves of airstrikes across large parts of Lebanon and killed Hezbollah's top leader, Hassan Nasrallah, and several top commanders. The Israeli military said some of the projectiles fired Sunday were intercepted. Israel's Magen David Adom rescue service said it treated seven people, including a 60-year old man in severe condition from rocket fire on northern Israel, a 23-year-old man who was lightly wounded by a blast in the central city of Petah Tikva and a 70-year-old woman who suffered smoke inhalation from a car that caught fire there. In Haifa, a rocket hit a residential building that police said was in danger of collapsing. It was unclear whether the injuries and damage were caused by rockets or interceptors. Israeli airstrikes without warning on Saturday pounded central Beirut, killing at least 20 people and wounding 66, according to Lebanon's Health Ministry. Smoke billowed above Beirut again Sunday with new strikes. Israeli attacks have killed more than 3,500 people in Lebanon, according to the Health Ministry. The fighting has displaced about 1.2 million people, or a quarter of Lebanon's population. On the Israeli side, about 90 soldiers and nearly 50 civilians have been killed by bombardments in northern Israel and in battle following Israel's ground invasion in early October. Around 60,000 Israelis have been displaced from the country's north. EU envoy calls for pressure to reach a truce The Biden administration has spent months trying to broker a cease-fire, and US envoy Amos Hochstein was in the region last week. The European Union's top diplomat called Sunday for more pressure on Israel and Hezbollah to reach a deal, saying one was "pending with a final agreement from the Israeli government". Josep Borrell spoke after meeting with Mikati and Lebanese Parliament Speaker Nabih Berri, a Hezbollah ally who has been mediating with the group. Borrell said the EU is ready to allocate 200 million euros (USD 208 million) to assist the Lebanese military, which would deploy additional forces to the south. The emerging agreement would pave the way for the withdrawal of Hezbollah militants and Israeli troops from southern Lebanon below the Litani River in accordance with the UN Security Council resolution that ended the month-long 2006 war. Lebanese troops would patrol the area, with the presence of UN peacekeepers. Lebanon's army reflects the religious diversity of the country and is respected as a national institution, but it does not have the military capability to impose its will on Hezbollah or resist Israel's invasion. (You can now subscribe to our Economic Times WhatsApp channel )
Preview: Nice vs. Le Havre - prediction, team news, lineups
Supreme Court seems likely to uphold Tennessee's ban on treatments for transgender minorsFinal regular-season games loom large in determining conference championship matchupsRobert Fernandez, one of Pearl Harbor attack’s last survivors, dies at 100
Meta to build $10 billion AI data center in Louisiana as Elon Musk expands his Tennessee AI facility
Boys soccer photos: No. 12 Randolph vs. No. 6 Shawnee, Group 3 final, Nov. 24, 2024MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuardTM Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his insights will be invaluable as the Company rapidly approaches potential U.S. approval of CGuard Prime, the most significant value inflection point in its history. I look forward to Scott's contributions and believe he will have an immediate impact.” Marvin Slosman, Chief Executive Officer of InspireMD and Board member, commented, "The addition of Scott to our Board adds tremendous experience in the cardiovascular field, with a track record of growth and innovation as an executive, a board member and investor. His experience and legacy in the space will help guide us through our next stages of advancing our novel carotid platform as part of a comprehensive approach to catalyzing on the market shift toward a stent first standard while also guiding our pipeline of innovation, including our CAS, TCAR and Neuro focus.” "I am very excited to join the InspireMD Board at such a transformational time for the company,” added Mr. Ward. "With an impressive body of data demonstrating the superior short- and long-term patient outcomes of its novel CGuard Prime carotid stent system, I believe that CGuard, when approved in the U.S., will quickly become a new standard-of-care for carotid intervention and stroke prevention. I look forward to working with my fellow Board members and the InspireMD leadership team to achieve this goal.” Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet ® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com . Forward-looking Statements This press release contains "forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. Such statements may be preceded by the words "intends,” "may,” "will,” "plans,” "expects,” "anticipates,” "projects,” "predicts,” "estimates,” "aims,” "believes,” "hopes,” "potential”, "scheduled” or similar words. Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's or directors' expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch.. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot be predicted or quantified and consequently; actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders' ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 [email protected] Chuck Padala, Managing Director LifeSci Advisors 646-627-8390 [email protected] [email protected]
Supreme Court seems likely to uphold Tennessee's ban on treatments for transgender minorsEditorial: 'Ghost gun' in CEO's murder highlights an industry custom-made for crime